

18 June 2021

Diaceutics PLC
("Diaceutics" or "the Company")

Purchase of Shares and PDMR Shareholding

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company for precision testing announces that on 17 June 2021, Deborah Davis, the Chair of Diaceutics, purchased a total of 27,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares"). Of these, 20,000 were purchased at a price of 130 pence per Ordinary Share, and 7,000 at a price of 128 pence per Ordinary Share. As a result of the purchase, Deborah's shareholding is 27,000 Ordinary Shares, representing approximately 0.03% of the Company's issued share capital.

Enquiries:

Diaceutics PLC

Philip White, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison
Stewart Wallace
Nick Adams

Alma PR

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

Caroline Forde
Robyn Fisher
Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Deborah Davis
2 Reason for notification		
a.	Position/Status	Chair
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted								
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64						
b.	Nature of the transaction	Purchase						
c.	Price(s) and volume(s)	Share purchase: <table border="1" data-bbox="531 497 978 692"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>130 p</td> <td>20,000</td> </tr> <tr> <td>128 p</td> <td>7,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	130 p	20,000	128 p	7,000
Price(s)	Volume(s)							
130 p	20,000							
128 p	7,000							
d.	Date of the transaction	17 June 2021						
e.	Place of the transaction	AIM Market of the London Stock Exchange						

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFSARTIDLIL